留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

肿瘤靶向纳米递释系统存在问题的分析

李文清 邹豪 钟延强

李文清, 邹豪, 钟延强. 肿瘤靶向纳米递释系统存在问题的分析[J]. 药学实践与服务, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
引用本文: 李文清, 邹豪, 钟延强. 肿瘤靶向纳米递释系统存在问题的分析[J]. 药学实践与服务, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
LI Wenqing, ZOU Hao, ZHONG Yanqiang. Analysis of problems on tumor-targeting drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
Citation: LI Wenqing, ZOU Hao, ZHONG Yanqiang. Analysis of problems on tumor-targeting drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003

肿瘤靶向纳米递释系统存在问题的分析

doi: 10.3969/j.issn.1006-0111.2015.02.003

Analysis of problems on tumor-targeting drug delivery system

  • 摘要: 目的 探究目前肿瘤靶向纳米递释系统存在的问题。 方法 在全面搜集查阅有关文献的基础上, 对肿瘤靶向纳米递释系统研究现状进行归纳整理。 结果 从3个方面对肿瘤靶向纳米递释系统存在的问题以及新的发展趋势提出建议与对策。 结论 要在研究中取得突破, 需要对人体生理学及肿瘤生物学进行深入研究, 并在现有的给药策略和实验方法等方面进行调整。
  • [1] 傅刘鹏,徐 俊,黄思超,等. 叶酸脂质体对乳腺癌4T1细胞的体内靶向性研究[J].山东医药, 2010,50(7):23-25.
    [2] 高 芸,李少一,商雪莹,等. FAT10过表达对肝癌细胞HepG2侵袭及迁移能力的影响[J].实用预防医学, 2013,20(5):517-520.
    [3] Giovanna D, Maurizio D. Contemporary pre-clinical development of anticancer agents-What are the optimal preclinical models?[J].Eur J Cancer,2009,45(16):2768-2781.
    [4] Lu W, Xiong C, Zhang R, et al.Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors[J]. J Control Release,2012, 161(3): 959-966.
    [5] Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities[J].J Control Release, 2010,141(3): 265-276.
    [6] Yoo HS,Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles[J]. J Control Release, 2004,96(2): 273-283.
    [7] Chung YI,Kima JC,Kim YH,et al.The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronie on tumor targeting[J].J Control Release,2010,143(3):374-382.
    [8] Kirpotin DB,Drummond DC, Shao Y,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models[J].Cancer Res,2006,66(13): 6732-6740.
    [9] Rooy I, Mastrobattista E, Storm G, et al. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain[J]. J Control Release, 2011,150(1): 30-36.
    [10] Bareford LM, Swann PW. Endocytic mechanisms for targeted drug delivery[J]. Adv Drug Deliv Rev, 2007,59(8) :748-758.
    [11] Paulos CM,Reddy JA, Leamon CP, et al. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery[J]. Mol Pharmacol, 2004,66(6): 1406-1414.
    [12] Smet M, Heijman E, Langereis S,et al. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof of concept study[J].J Control Release, 2011,150(1): 102-110.
    [13] Chen H, Kim S, He W, et al. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Forster resonance energy transfer imaging[J]. Langmuir, 2008,24(10): 5213-5217.
    [14] Chen H, Kim S, Li L, et al. Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging[J]. Proc Natl Acad Sci USA, 2008,105(18): 6596-6601.
    [15] Koo AN, Min KH, Lee HJ, et al.Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links[J]. Biomaterials, 2012,33(5): 1489-1499.
    [16] Ishida T, Ichihara M, Wang X, et al. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes[J]. J Control Release, 2006,115(3): 243-250.
    [17] Lu W,Wan J,She Z,et al.Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle[J].J Control Release,2007,118(1):38-53.
    [18] Park K. To PEGylate or not to PEGylate, that is not the question[J]. J Control Release, 2010,142(2): 147-148.
    [19] Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy[J]. Biochem Pharmacol, 2010,80(5): 762-770.
    [20] Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells[J]. Cancer Res, 2006,66(2): 1033-1039.
    [21] Netti PA, Berk DA, Swartz M A,et al. Role of etracellular matrix assembly in interstitial transport in solid tumors[J]. Cancer Res, 2000,60(9): 2497-2503.
    [22] Brown E, Mckee TD, Tomaso ED, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation[J]. Nat Med, 2003,9(6): 796-800.
    [23] Ramanujan S, Pluen A, Mckee TD, et al. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium[J]. Biophys J, 2002,83(3): 1650-1660.
    [24] Alexandrakis G, Brown E, Tong RT, et al. Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors[J]. Nat Med, 2004,10(2): 203-207.
    [25] Ernsting MJ, Murakami M, Roy A, et al. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles[J]. J Control Release, 2013,172(3): 782-794.
    [26] Damia G, D'Incalci M. Contemporary pre-clinical development of anticancer agents-what are the optimal preclinical models[J]. Eur J Cancer, 2009,45(16): 2768-2781.
  • [1] 周洛竹, 盛春泉.  靶向蛋白降解技术研究进展与展望 . 药学实践与服务, 2023, 41(6): 341-351, 365. doi: 10.12206/j.issn.2097-2024.202303008
    [2] 徐圣弢, 吴琼, 刘佃花, 王琳召, 谭蔚锋, 陈俊.  基于中心碳代谢分析技术的肝胆系统疾病靶向代谢组学研究 . 药学实践与服务, 2023, 41(12): 753-759. doi: 10.12206/j.issn.2097-2024.202302040
    [3] 张晶, 顾永卫, 武鑫.  适配体C2min介导的可靶向2种前列腺癌基因的递送系统 . 药学实践与服务, 2020, 38(1): 47-51,66. doi: 10.3969/j.issn.1006-0111.201906038
    [4] 程丹, 许幼发, 傅志勤, 陈建明.  靶向肿瘤微环境的紫杉醇前药研究进展 . 药学实践与服务, 2018, 36(1): 1-8. doi: 10.3969/j.issn.1006-0111.2018.01.001
    [5] 刘丹, 张军东, 廉云飞, 房秋雨, 李娟.  核-壳结构的脂质-聚合物杂化纳米粒的研究进展 . 药学实践与服务, 2018, 36(1): 13-17. doi: 10.3969/j.issn.1006-0111.2018.01.003
    [6] 刘曼, 刘丽云, 孙凡, 林厚文.  靶向肺癌干细胞的海绵抗肿瘤活性化合物的发现 . 药学实践与服务, 2017, 35(4): 304-307. doi: 10.3969/j.issn.1006-0111.2017.04.005
    [7] 姜文丽, 黄才国.  晚期非小细胞肺癌靶向治疗的研究进展 . 药学实践与服务, 2016, 34(4): 301-304,333. doi: 10.3969/j.issn.1006-0111.2016.04.004
    [8] 樊鹏程, 葛越, 蒋炜, 景临林, 马慧萍, 贾正平.  线粒体靶向抗氧化剂研究进展 . 药学实践与服务, 2015, 33(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2015.01.001
    [9] 于淼, 毛峻琴.  基因miRNA-34a靶向纳米复合物抗前列腺癌细胞增殖的作用研究 . 药学实践与服务, 2015, 33(6): 539-543. doi: 10.3969/j.issn.1006-0111.2015.06.016
    [10] 熊叶, 台宗光, 李强.  核苷酸适体在靶向给药系统中的应用进展 . 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
    [11] 蒋琦, 钱其军.  化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展 . 药学实践与服务, 2015, 33(2): 163-166,182. doi: 10.3969/j.issn.1006-0111.2015.02.019
    [12] 高洪元, 吴建勇, 倪曙民.  双级靶向纳米载体在脑肿瘤诊断和治疗方面的应用 . 药学实践与服务, 2015, 33(1): 9-12,16. doi: 10.3969/j.issn.1006-0111.2015.01.003
    [13] 周琴琴, 陈建明.  清蛋白作为药物载体的PEG化修饰研究进展 . 药学实践与服务, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
    [14] 吴韫韬, 张依依.  聚合物胶束作为药物载体及其在肿瘤靶向方面的研究进展 . 药学实践与服务, 2013, 31(2): 86-89,115. doi: 10.3969/j.issn.1006-0111.2013.02.002
    [15] 王晓宇, 高静, 张玮, 朱全刚, 武鑫, 高申.  细胞外激活纳米载药系统研究进展 . 药学实践与服务, 2012, 30(1): 4-7,57. doi: 10.3969/j.issn.1006-0111.2012.01.002
    [16] 黄景彬, 钟延强.  乳腺癌靶向治疗的新策略 . 药学实践与服务, 2011, 29(5): 324-327.
    [17] 陈婷, 鲁莹.  载抗肿瘤药物纳米靶向给药系统的研究进展 . 药学实践与服务, 2011, 29(3): 176-178,196.
    [18] 官东秀, 冯祚臻.  临床药师对1例服用分子靶向药物吉非替尼的肿瘤患者的药学监护 . 药学实践与服务, 2010, 28(4): 310-312.
    [19] 薛龙, 孙爱军.  恶性肿瘤靶向治疗方法的进展及应用 . 药学实践与服务, 2008, (2): 81-83.
    [20] 侯雪梅, 崔黎丽, 李国栋, 李卫华.  抗肿瘤药物靶向制剂研究进展 . 药学实践与服务, 2007, (5): 273-275,280.
  • 加载中
计量
  • 文章访问数:  2029
  • HTML全文浏览量:  166
  • PDF下载量:  641
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-01-14
  • 修回日期:  2014-09-23

肿瘤靶向纳米递释系统存在问题的分析

doi: 10.3969/j.issn.1006-0111.2015.02.003

摘要: 目的 探究目前肿瘤靶向纳米递释系统存在的问题。 方法 在全面搜集查阅有关文献的基础上, 对肿瘤靶向纳米递释系统研究现状进行归纳整理。 结果 从3个方面对肿瘤靶向纳米递释系统存在的问题以及新的发展趋势提出建议与对策。 结论 要在研究中取得突破, 需要对人体生理学及肿瘤生物学进行深入研究, 并在现有的给药策略和实验方法等方面进行调整。

English Abstract

李文清, 邹豪, 钟延强. 肿瘤靶向纳米递释系统存在问题的分析[J]. 药学实践与服务, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
引用本文: 李文清, 邹豪, 钟延强. 肿瘤靶向纳米递释系统存在问题的分析[J]. 药学实践与服务, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
LI Wenqing, ZOU Hao, ZHONG Yanqiang. Analysis of problems on tumor-targeting drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
Citation: LI Wenqing, ZOU Hao, ZHONG Yanqiang. Analysis of problems on tumor-targeting drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
参考文献 (26)

目录

    /

    返回文章
    返回